Compare · AVNS vs STE
AVNS vs STE
Side-by-side comparison of Avanos Medical Inc. (AVNS) and STERIS plc (Ireland) (STE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AVNS and STE operate in Industrial Specialties (Health Care), so they compete in similar markets.
- STE is the larger of the two at $21.26B, about 18.2x AVNS ($1.17B).
- Over the past year, AVNS is up 119.1% and STE is down 2.1% - AVNS leads by 121.2 points.
- AVNS has been more active in the news (5 items in the past 4 weeks vs 1 for STE).
- STE has more recent analyst coverage (16 ratings vs 7 for AVNS).
- Company
- Avanos Medical Inc.
- STERIS plc (Ireland)
- Price
- $24.98+0.04%
- $217.88-1.46%
- Market cap
- $1.17B
- $21.26B
- 1M return
- +0.04%
- +5.46%
- 1Y return
- +119.12%
- -2.08%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NYSE
- NYSE
- IPO
- 2014
- News (4w)
- 5
- 1
- Recent ratings
- 7
- 16
Avanos Medical Inc.
Avanos Medical, Inc. operates as a medical technology company that focuses on delivering medical device solutions to improve patients' quality of life in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps and Game Ready cold and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain relieving therapies, such as Coolief pain relief therapy. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
STERIS plc (Ireland)
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. This segment offers its products and services to acute care hospitals and other healthcare settings. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The company is based in Dublin, Ireland.
Latest AVNS
- SEC Form DEFA14A filed by Avanos Medical Inc.
- Avanos Medical Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form DEFA14A filed by Avanos Medical Inc.
- Avanos Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Avanos Medical, Inc. and American Industrial Partners Receive Required Regulatory Approvals for Pending Merger
- SEC Form DEFM14A filed by Avanos Medical Inc.
- SEC Form SD filed by Avanos Medical Inc.
- SEC Form PREM14A filed by Avanos Medical Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Avanos Medical Inc.
- SEC Form 4 filed by Director Blackford Gary
Latest STE
- Director Sohi Mohsen exercised 3,781 units of Ordinary Shares at a strike of $71.40 and covered exercise/tax liability with 1,837 units of Ordinary Shares, increasing direct ownership by 9% to 24,305 units (SEC Form 4)
- SEC Form 11-K filed by STERIS plc (Ireland)
- Sr. VP, Gen Counsel, and Sec. Zangerle John Adam sold $296,968 worth of Ordinary Shares (1,419 units at $209.28), decreasing direct ownership by 4% to 35,259 units (SEC Form 4)
- SEC Form 144 filed by STERIS plc (Ireland)
- Sr. VP, Gen Counsel, and Sec. Zangerle John Adam covered exercise/tax liability with 401 units of Ordinary Shares, decreasing direct ownership by 1% to 36,678 units (SEC Form 4)
- V.P. & Corporate Treasurer Tamaro Renato covered exercise/tax liability with 65 units of Ordinary Shares, decreasing direct ownership by 1% to 6,194 units (SEC Form 4)
- Sr. VP and GM, Life Sciences Madsen Julia covered exercise/tax liability with 195 units of Ordinary Shares, decreasing direct ownership by 2% to 12,257 units (SEC Form 4)
- SVP & GM, AST Kohler Kenneth E covered exercise/tax liability with 150 units of Ordinary Shares, decreasing direct ownership by 1% to 11,332 units (SEC Form 4)
- SVP & Chief HRO Fraser Mary Clare covered exercise/tax liability with 600 units of Ordinary Shares, decreasing direct ownership by 4% to 13,716 units (SEC Form 4)
- President and CEO Carestio Daniel A covered exercise/tax liability with 1,889 units of Ordinary Shares and sold $946,799 worth of Ordinary Shares (4,428 units at $213.82), decreasing direct ownership by 9% to 63,647 units (SEC Form 4)